Who are Nplate's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Mulpleta, Doptelet, Promacta, CsA+Herombopag, Nplate, TPO.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/romiplostim.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Nplate — Competitive Intelligence Brief

Nplate (ROMIPLOSTIM) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Thrombopoietin Receptor Agonist [EPC]. Area: Cardiovascular.

marketed Thrombopoietin Receptor Agonist [EPC] Thrombopoietin receptor Cardiovascular Recombinant protein Live · refreshed every 30 min

Target snapshot

Nplate (ROMIPLOSTIM) — Amgen. Nplate works by binding to the thrombopoietin receptor to stimulate platelet production.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Nplate TARGET	ROMIPLOSTIM	Amgen	marketed	Thrombopoietin Receptor Agonist [EPC]	Thrombopoietin receptor	2008-01-01
Mulpleta	LUSUTROMBOPAG	Vancocin Italia	marketed		Thrombopoietin receptor	2018-01-01
Doptelet	AVATROMBOPAG	Akarx Inc	marketed		Thrombopoietin receptor	2018-01-01
Promacta	ELTROMBOPAG	Novartis	marketed	Thrombopoietin Receptor Agonist	Thrombopoietin receptor	2008-01-01
CsA+Herombopag	CsA+Herombopag	Peking Union Medical College Hospital	marketed	Combination therapy: calcineurin inhibitor + thrombopoietin receptor agonist	Calcineurin (CsA); thrombopoietin receptor / MPL (herombopag)
Nplate	Nplate	Nantes University Hospital	marketed		Thrombopoietin receptor
TPO	TPO	Shenyang Sunshine Pharmaceutical Co., LTD.	marketed	Thrombopoietin receptor agonist	c-Mpl (thrombopoietin receptor)

Recent regulatory actions (last 90 days)

2026-03-16 — Promacta · FDA · approved · US · Novartis

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Thrombopoietin Receptor Agonist [EPC] class)

Amgen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Nplate — Competitive Intelligence Brief. https://druglandscape.com/ci/romiplostim. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab